BRAIN Biotech AG (BNN.DE)
EUR 3.77
(-3.58%)
EUR 3.77
(-3.58%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -8.27 Million EUR | -30.56% |
| 2022 | -6.34 Million EUR | -35.52% |
| 2021 | -4.67 Million EUR | 48.11% |
| 2020 | -9.01 Million EUR | 14.08% |
| 2019 | -10.49 Million EUR | -26.81% |
| 2018 | -8.27 Million EUR | 13.85% |
| 2017 | -9.6 Million EUR | 34.6% |
| 2016 | -14.68 Million EUR | -157.06% |
| 2015 | -5.71 Million EUR | -13.28% |
| 2014 | -5.04 Million EUR | -23.18% |
| 2013 | -4.09 Million EUR | 26.04% |
| 2012 | -5.53 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -2.57 Million EUR | 43.66% |
| 2024 Q1 | -2.64 Million EUR | -61.38% |
| 2024 Q2 | -4.56 Million EUR | -72.51% |
| 2023 Q1 | -2.45 Million EUR | -1705.88% |
| 2023 Q4 | -1.63 Million EUR | 11.12% |
| 2023 FY | -8.27 Million EUR | -30.56% |
| 2023 Q3 | -1.84 Million EUR | 14.31% |
| 2023 Q2 | -2.15 Million EUR | 12.38% |
| 2022 Q2 | -1.41 Million EUR | 39.21% |
| 2022 FY | -6.34 Million EUR | -35.52% |
| 2022 Q4 | -136 Thousand EUR | 94.46% |
| 2022 Q3 | -2.45 Million EUR | -73.39% |
| 2022 Q1 | -2.33 Million EUR | -40.85% |
| 2021 Q1 | -3.35 Million EUR | -5.53% |
| 2021 FY | -4.67 Million EUR | 48.11% |
| 2021 Q2 | 2.07 Million EUR | 161.68% |
| 2021 Q4 | -1.65 Million EUR | 18.51% |
| 2021 Q3 | -2.03 Million EUR | -198.12% |
| 2020 Q4 | -3.18 Million EUR | -81.4% |
| 2020 Q1 | -2.25 Million EUR | 4.16% |
| 2020 Q3 | -1.75 Million EUR | 29.71% |
| 2020 Q2 | -2.49 Million EUR | -10.45% |
| 2020 FY | -9.01 Million EUR | 14.08% |
| 2019 FY | -10.49 Million EUR | -26.81% |
| 2019 Q4 | -2.35 Million EUR | 40.92% |
| 2019 Q3 | -3.98 Million EUR | -41.67% |
| 2019 Q1 | -1.31 Million EUR | -5.36% |
| 2019 Q2 | -2.81 Million EUR | -113.74% |
| 2018 Q2 | -2.35 Million EUR | -2.12% |
| 2018 FY | -8.27 Million EUR | 13.85% |
| 2018 Q4 | -1.25 Million EUR | 41.48% |
| 2018 Q3 | -2.13 Million EUR | 9.41% |
| 2018 Q1 | -2.3 Million EUR | -11.06% |
| 2017 Q3 | -1.65 Million EUR | -26.59% |
| 2017 Q1 | -4.56 Million EUR | 25.68% |
| 2017 Q2 | -1.3 Million EUR | 71.3% |
| 2017 FY | -9.6 Million EUR | 34.6% |
| 2017 Q4 | -2.07 Million EUR | -25.47% |
| 2016 Q4 | -6.13 Million EUR | -146.39% |
| 2016 FY | -14.68 Million EUR | -157.06% |
| 2016 Q3 | -2.49 Million EUR | 32.54% |
| 2016 Q2 | -3.69 Million EUR | -55.8% |
| 2016 Q1 | -2.36 Million EUR | -112.34% |
| 2015 Q1 | -750.8 Thousand EUR | 0.0% |
| 2015 FY | -5.71 Million EUR | -13.28% |
| 2015 Q2 | -1.95 Million EUR | -160.79% |
| 2015 Q3 | -1.88 Million EUR | 3.49% |
| 2015 Q4 | -1.11 Million EUR | 40.94% |
| 2014 FY | -5.04 Million EUR | -23.18% |
| 2013 FY | -4.09 Million EUR | 26.04% |
| 2012 FY | -5.53 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioNTech SE | 930.3 Million EUR | 100.89% |
| CureVac N.V. | -260.16 Million EUR | 96.818% |
| Biotest Aktiengesellschaft | 127 Million EUR | 106.519% |
| Biotest Aktiengesellschaft | 127 Million EUR | 106.519% |
| Formycon AG | 75.79 Million EUR | 110.923% |
| Heidelberg Pharma AG | -20.34 Million EUR | 59.31% |
| Medigene AG | -16.17 Million EUR | 48.822% |